Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has expanded its partnership with pharmaceutical giant MSD, providing MSD with the option to license two of Evaxion’s AI-designed preclinical vaccine candidates, EVX-B2 for Gonorrhea and EVX-B3 for an undisclosed infectious disease. Under the new agreement, Evaxion is set to receive an upfront payment of $3.2 million and could receive up to $592 million per product in milestone payments, plus royalties on sales. This collaboration underscores the industry’s confidence in Evaxion’s innovative AI-Immunology platform and its potential to develop effective vaccines.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
